Form 4: Xilio Therapeutics CFO Christopher Frankenfield Reports Stock Transactions

Christopher Frankenfield, CFO of Xilio Therapeutics, reports the vesting of restricted stock units, a sale of shares to cover tax obligations, and the grant of stock options.

Summary

• On January 1, 2025, Christopher Frankenfield, the CFO of Xilio Therapeutics, had 19,375 restricted stock units (RSUs) vest, which converted to common stock on a one-for-one basis.
• Also on January 1, 2025, Frankenfield was granted a stock option to purchase 251,000 shares of common stock at an exercise price of $0.955.
• On January 2, 2025, Frankenfield sold 6,954 shares of common stock at a price of $0.9837 per share.
• This sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations related to the vesting of the RSUs.
• Following these transactions, Frankenfield directly owns 12,421 shares of Xilio Therapeutics common stock and holds options for 251,000 shares.
• The RSUs granted on January 1, 2024, vest in four equal annual installments starting January 1, 2025, and continuing through January 1, 2028.
• The stock options granted on January 1, 2025, vest in 48 equal monthly installments beginning February 1, 2025, and continuing through January 1, 2029.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative sentiment. It simply reflects the execution of pre-existing compensation plans.

Future Outlook

The document outlines the vesting schedules for both the RSUs and stock options, indicating future equity compensation events for the reporting person.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the equity holdings and transactions of company executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the overall effect is likely minimal.
• The vesting of RSUs and granting of stock options are part of the executive compensation plan, impacting the executive's personal financial situation.

Key Dates